Hello, Fool! | Login | Signup | My Fool
Nov 19, 2008 7:12 PM ET | Feedback | Site Changes | Help
A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease.
View Ticker Page (ALKS)
Results 21 - 28 of 28 : 123
Recs
RumbleDog (< 20) Submitted: 1/18/07 2:41 PM : Start Price: $14.94 ALKS Score: -13.16
Vivatrol will gain wider acceptance, Air inslulin will be approved and welcomed. New partners will come on board to diversify the company's stable.
Report this Post Replies: 0 | Reply | Permalink
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
mfly (41.41) Submitted: 3/30/07 4:11 PM : Start Price: $15.41 ALKS Score: -14.63
solid product direction, new product just now being adopted
TMFTurbo (< 20) Submitted: 4/13/07 9:26 AM : Start Price: $15.55 ALKS Score: -13.94
CAPS Recommendation
steveku2 (< 20) Submitted: 4/13/07 2:22 PM : Start Price: $15.44 ALKS Score: -13.56
Small pharmaceutical, making "behavior modification" drugs. Actively pursuing global sales. Partnering with other companies. A tough little mini- to mid-cap.
hihoterry (< 20) Submitted: 4/18/07 4:18 PM : Start Price: $16.55 ALKS Score: -15.87
rising sales of vivitrol, good pipe line and continued expansion of sales in other marketed products
1ct (47.25) Submitted: 6/06/07 2:11 PM : Start Price: $15.52 ALKS Score: -11.24
biotech play with multiple product lines
TrademDave (69.22) Submitted: 9/11/07 11:29 AM : Start Price: $16.56 ALKS Score: -15.76
ALKS has a good pipeline and good partnership with major drug companies. Current price is in the upper mid range of the 52wk hi-lo. Good buy in the 16.50 range.
zzlangerhans (99.34) Submitted: 10/13/08 1:50 PM : Start Price: $11.96 ALKS Score: -22.86
Risperdal Consta revenues continue to increase and have become the backbone of the franchise. Meanwhile, the stock has been pressured by concerns about the future of Exenatide given the problems with Byetta. I remain bullish on both Alkermes and Amyl...
Terms & Conditions
RSS Headlines
Fool UK